603716
vs
S
Shanghai Composite
603716
Over the past 12 months, Thalys Medical Technology Group Inc has significantly outperformed Shanghai Composite, delivering a return of +103% compared to the Shanghai Composite's +22% growth.
Stocks Performance
603716 vs Shanghai Composite
Performance Gap
603716 vs Shanghai Composite
Performance By Year
603716 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Thalys Medical Technology Group Inc
Glance View
Thalys Medical Technology Group, Inc. engages in the research, development, production, and sale of in vitro diagnostic products. The company is headquartered in Wuhan, Hubei and currently employs 1,637 full-time employees. The company went IPO on 2016-10-31. Its product type includes purchased reagents and consumables, self-produced reagents and consumables, as well as purchased equipment. The firm mainly operates its business in domestic markets, with Hubei, Hunan, Jiangsu, Henan and Shanghai province as its major markets.